Phase 3 Study of LY4170156 for Ovarian Cancer Resistant or Sensitive to Platinum Treatment

Inclusion Criteria

Part A and B:

• Diagnosed with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer.
• Have tumor tissue samples available for testing.
• Cancer has progressed after the most recent cancer treatment.
• In good general health, able to carry out daily activities (ECOG score 0-1).
• Have measurable cancer as per standard criteria.

Part A:

• Cancer has become resistant to platinum treatments, meaning it progressed within 6 months after the last platinum therapy.
• Have had 1 to 3 previous chemotherapy treatments, or up to 4 if one included mirvetuximab soravtansine.
• Have received bevacizumab treatment unless unable to due to medical reasons.
• Have had treatment with a PARP inhibitor if there is a BRCA mutation, unless unable to due to medical reasons.

Part B:

• Cancer returned after initial platinum-based chemotherapy and is still sensitive to platinum, meaning it progressed more than 6 months after the last platinum therapy.
• Have had 1 to 2 previous chemotherapy treatments.
• Have used a PARP inhibitor and experienced progression during or within 6 months after completing the treatment.

Exclusion Criteria

Part A and B:

• Have previously received a specific type of drug called an antibody-drug conjugate with a topoisomerase inhibitor.

Part A:

• Have cancer that did not respond to the first platinum treatment, progressing within 3 months after the last dose.

Part B:

• Have significant protein in the urine.